Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 11/20 | 0.77 |
| ▸ | NAMPT | P43490 | 6/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377441 | 0.87 | GHSR (1.00) | GHSRNAMPT | |
| SCHEMBL19377322 | 0.84 | GHSR (0.59) | GHSRNAMPT | |
| SCHEMBL20379606 | 0.77 | NAMPT (1.00) | NAMPT | |
| SCHEMBL20388977 | 0.76 | NAMPT (0.85) | NAMPTCA12CA1CA2CA9 | |
| SCHEMBL20379238 | 0.75 | NAMPT (0.93) | NAMPT | |
| SCHEMBL20671535 | 0.75 | NAMPT (0.67) | GHSRNAMPTCA12CA1CA2 | |
| SCHEMBL19377093 | 0.75 | GHSR (0.54) | GHSR | |
| SCHEMBL19377095 | 0.75 | GHSR (0.54) | GHSR | |
| SCHEMBL5310949 | 0.74 | HDAC1 (0.62) | GHSRNAMPTCA12CA1CA2 | |
| SCHEMBL162432 | 0.74 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | GHSR 2/4885NAMPT 3742/4885CA12 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.